The three compounds are BL-1030, a small molecule for the treatment of inflammatory bowel disease, BL-1050, a novel HIV therapeutic, and BL-2010, an innovative technology for the treatment
Under the agreement, Aceto will source the active pharmaceutical ingredients, manage the regulatory and quality control functions of production, and supply the final dosage form of the products
DG041 is a novel, first-in-class, orally-administered small molecule for the treatment of peripheral arterial occlusive disease (PAOD). In pre-clinical studies, DG041 has been shown to be a selective
This is the first of two phase I/II trials to be initiated. The second trial will be conducted in Europe and is likely to be initiated in the
In this study, patients who met the relevant criteria (either newly diagnosed or patients who have relapsed) for both insomnia and major depressive disorder (MDD), were randomized to
Forbes announced revenue guidance of C$21 to C$22 million for fiscal 2005 for the period ending December 31, 2005. This anticipated revenue represents a minimum 20% growth versus
The Vaccine Research Center (VRC) will utilize GenVec’s proprietary technologies for vaccine development, including its production cell line, 293-ORF6, to design and test next generation vaccines to optimize
The special protocol assessment (SPA) from the FDA documents agreement on the protocol under which Avanir will conduct and analyze the data from a pivotal trial evaluating the
The study is being conducted under an investigational new drug (IND) application that Memory Pharmaceuticals filed with the FDA in mid-November 2004. The safety and tolerability study is
Biovail’s new drug application (NDA) for this formulation was accepted for review by the FDA in May 2004. The approvable letter involves the resolution of labeling issues only,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.